MYCN and neuroblastoma: While these studies were performed prior to the prognostic use of MYCN amplification and therefore did not consider MYCN amplification status, MYCN amplification is now known to occur in approximately 20% of primary neuroblastomas [7, 8], and is likely to be over-represented in a trial enrolling patients with metastatic disease [32].